Nathan Sheets, MD
University of North Carolina |
Comparative effectiveness of intensity modulated radiation therapy (IMRT), proton therapy (PT), and conformal radiation therapy (CRT) in the treatment of localized prostate cancer. (Abstract #3) |
Eugene Cha, MD
Weill Cornell Medical College, Department of Urology |
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. (Abstract #267) |
Petros Grivas, MD, PhD
University of Michigan |
Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). (Abstract #265) |
Phillip Palmbos, MD, PhD
University of Michigan |
ATDC as a novel oncogene in bladder cancer. (Abstract #269) |
Michael Rink, MD
Weill Cornell Medical College |
Influence of preoperatively detected circulating tumor cells on the outcome of patients with urothelial carcinoma of the bladder treated with radical cystectomy. (Abstract #268) |
Xueying Mao, MS
Queen Mary University of London |
The different genetic alterations between Western and Chinese prostate cancers and the underlying mechanisms. (Abstract #184). |
Phillip Gray, MD
Brigham and Women's Hospital |
Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. (Abstract #22) |
Mark Jesus Magbanua, PhD
University of California San Francisco |
Physical activity and prostate gene expression in men with low-risk prostate cancer. (Abstract #189) |
Christopher Hallemeier, MD
Mayo Clinic |
Long-term outcomes of radiotherapy for stage II testicular seminoma: The Mayo Clinic experience. (Abstract #327) |
Kenneth Nepple, MD
Washington University School of Medicine |
Impact of different definitions of high-risk prostate cancer on survival after radical prostatectomy. (Abstract #113) |
David Margel, MD
University of Toronto |
Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study. (Abstract #30) |
Che-Kai Tsao, MD
Tisch Cancer Institute, Mount Sinai Medical Center |
Cytoreductive nephrectomy in the United States: Patterns of care and patient characteristics. (Abstract #366) |
Adrian Fairey, MD, MS
University of Southern California Keck School of Medicine |
Association between cancer stem-like cell gene expression and clinical outcome in localized prostate cancer: A nested case-control study. (Abstract #31) |
Thai Ho, MD, PhD
University of Texas M. D. Anderson Cancer Center |
Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC). (Abstract #368) |
Monica Shukla, MD
Cleveland Clinic |
Identifying patients with node-positive prostate cancer who may benefit from adjuvant pelvic radiation following prostatectomy. (Abstract #195) |
Ben Tran, MBBS
Princess Margaret Hospital |
Impact of renal impairment and granulocyte colony stimulating factor (GCSF) on bleomycin-induced pneumonitis (bleo lung), febrile neutropenia (FN), and survival in patients (pts) with germ cell tumor (GCT) treated with chemotherapy (chemo). (Abstract #328) |
Erin Richman, ScD
University of California San Francisco |
Genetic variants in antioxidant genes, Gleason grade, and prostate cancer recurrence after radical prostatectomy. (Abstract #33) |
Arjun Balar, MD
Memorial Sloan-Kettering Cancer Center |
Alterations in the PI3K/Αkt signaling pathway and association with outcome in invasive high-grade urothelial cancer (UC). (Abstract #277) |
James Chen, MD
The University of Chicago |
Role of homeobox pathway in prostate carcinogenesis. (Abstract #126) |
Brian Shuch, MD
National Cancer Institute |
Metabolic evaluation of sporadic papillary kidney cancer. (Abstract #377) |